Central nervous system paracoccidioidomycosis. Report of a case successfully treated with itraconazol

L A Villa1, A Tobón, A Restrepo

  • 1Departamento de Neurología, Facultad de Medicina, Hospital Universitario San Vicente, Universidad de Antioquia, Colombia.

Insights

Neuroparacoccidioidomycosis (NPCM), a rare central nervous system infection, presents diagnostic challenges. Successful treatment requires careful management of drug interactions, particularly with itraconazole therapy.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Neurology

Background:

  • Paracoccidioidomycosis (PCM) is a systemic fungal infection endemic to Latin America, primarily affecting the lungs.
  • Central nervous system (CNS) involvement, known as neuroparacoccidioidomycosis (NPCM), is infrequent but associated with significant morbidity.
  • Delayed diagnosis and treatment in NPCM can lead to severe neurological complications.

Observation:

  • A 55-year-old male presented with a month of progressive neurological symptoms including hemiparesis, paresthesias, ptosis, headache, vomiting, and seizures.
  • Physical examination revealed an abdominal ulcerated granulomatous lesion.
  • Diagnosis was confirmed by identifying *P. brasiliensis* in bronchoalveolar lavage and brain biopsy specimens.

Findings:

  • Initial treatment with itraconazole (ITZ) was ineffective, suspected due to drug interaction with sodium valproate.
  • Altering seizure medication to clonazepam allowed for therapeutic ITZ plasma levels.
  • Clinical improvement correlated with decreasing fungal antigen and antibody titers after itraconazole therapy was optimized.

Implications:

  • NPCM should be considered in the differential diagnosis of neurological disorders in endemic regions.
  • Optimizing antifungal therapy by managing drug interactions is crucial for successful NPCM treatment.
  • This case highlights the importance of monitoring drug levels and interactions during treatment for invasive fungal infections.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...